Document:

EX-10.2

Exhibit 10.2

STOCK PURCHASE AGREEMENT

THIS STOCK PURCHASE AGREEMENT (this “Agreement”) by and between MDRNA, INC., a
Delaware corporation (the “Company”), and BIOMED REALTY, L.P., a Maryland limited
partnership (“BioMed”), is executed and effective as of March 5, 2009 (the “Effective
Date”).

RECITALS

WHEREAS, BMR-3450 Monte Villa Parkway LLC, a Delaware limited liability company (the
“Landlord,” as successor-in-interest to Phase 3 Science Center LLC), and the Company
entered into that certain Lease dated as of April 23, 2002, as amended by that certain First
Amendment to Lease dated as of July 1, 2003, that certain Second Amendment to Lease dated as of
January 29, 2004, and that certain Third Amendment to Lease dated as of the Effective Date (the
“Third Amendment,” and collectively, the “Lease”);

WHEREAS, pursuant to Section 6 of the Third Amendment, the Company and BioMed, the sole member of
the Landlord, enter into this Agreement pursuant to which the Company shall issue to BioMed, and
BioMed shall acquire from the Company, an aggregate of One Million Five Hundred Thousand
(1,500,000) shares (the “Shares”) of the Company’s common stock, par value $0.006 per share
(the “Common Stock”), on the terms and subject to the conditions specified herein.

NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the parties
hereto hereby agree as follows:

1. Issuance of Shares.

1.1 Issuance of Shares. On the Effective Date and subject to the terms and conditions
of this Agreement, in consideration of entering into the Third Amendment and for other good and
valuable consideration the sufficiency of which is hereby recognized, the Company agrees to issue
to BioMed, and BioMed agrees to acquire from the Company, the Shares.

1.2 Delivery of Shares. No later than five (5) business days following the Effective
Date, the Company shall deliver to BioMed or cause to be delivered to BioMed, a share certificate
registered in BioMed’s name representing the Shares that BioMed is to receive from the Company.

2. Representations and Warranties of the Company. The Company hereby represents and
warrants to BioMed as of the Effective Date, and with respect to Sections 2.7, 2.8, 2.9 and 2.10
for so long as BioMed holds the Shares, as follows:

2.1 Organization; Good Standing. The Company is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware and has all requisite
corporate power and authority to carry on its business as presently conducted and as proposed to be
conducted, and is qualified to do business as a foreign corporation in good standing in all other
jurisdictions in which the conduct of its business requires such qualification.

2.2 Authorization. All corporate action on the part of the Company, its respective
officers, directors and shareholders necessary for the authorization, execution and delivery of
this Agreement, the performance of all obligations of the Company hereunder, and the authorization,
issuance and delivery of the Shares has been taken, and this Agreement constitutes a valid and
legally binding obligation of the Company, enforceable in accordance with its terms. The Shares
being purchased by BioMed hereunder, when issued, sold and delivered in accordance with the terms
of this Agreement for the consideration expressed herein, will be duly and validly issued, fully
paid and nonassessable, and not subject to preemptive or other similar rights of the Company’s
stockholders or others.

2.3 Percentage of Outstanding Stock. The Shares represent less than five percent
(5.0%) of the voting interest and less than five percent (5.0%) of the value of the outstanding
stock of the Company.

2.4 Securities Laws. Subject to the accuracy of the representations and warranties of
BioMed set forth in Section 3 below, the offering, issuance and sale of the Shares to
BioMed is exempt from the registration requirements of Section 5 of the Securities Act of 1933, as
amended (“Securities Act”) by virtue of Rule 506 of Regulation D promulgated by the
Securities Act, and no consent, approval, qualification, registration or filing under any federal
or state securities law is required in connection therewith, except for the filing of a Form D,
which shall be filed with the Securities and Exchange Commission after the Shares are issued and
which the Company agrees to file in a timely manner whenever required. Rule 506 of Regulation D is
available to the offering, issuance, sale and delivery of the Shares to BioMed because, among other
things, (1) there has been no general solicitation or general advertisement in connection with such
offering, issuance and sale to BioMed, and (2) there are no other offerings of securities of the
Company which could be integrated with the offering, issuance and sale of the Shares contemplated
by this Agreement.

2.5 Restrictions. The Shares will be free of restrictions on transfer other than
restrictions on transfer set forth in this Agreement or as otherwise required by applicable federal
and state securities laws.

2.6 No Violation. Neither the execution, delivery and performance of this Agreement
by the Company nor the issuance, sale and delivery of the Shares contemplated hereby will violate,
conflict with or result in any breach of any of the terms, conditions or provisions of, constitute
a default under, or require any consent not obtained as of the Effective Date under, (1) the
certificate of incorporation or by-laws of the Company, (2) any agreement, contract, arrangement or
understanding to which the Company is a party (including, but not limited to, any shareholders’ or
similar agreements), or (3) any statute or any rule, regulation, order, judgment or decree of any
court or other governmental body applicable to the Company.

2.7 Health Care / Lodging Facilities. The Company does not operate or manage any
health care facilities (including a congregate care facility or assisted living facility) or
lodging facilities or provide any person, under a franchise, license or otherwise, rights to any
brand name under which any lodging facility or health care facility is operated.

2.8 Annual Reports. The Company shall furnish to BioMed, as soon as practicable and
in any event within 90 days after the end of each fiscal year of the Company, audited, consolidated
annual financial statements certified by an independent certified public accountant and prepared in
accordance with U.S. GAAP; provided, however, that so long as the Company remains subject to the
reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), the Company may satisfy this requirement by the timely filing of such financial
statements with the Securities and Exchange Commission.

2.9 Quarterly Information. The Company shall furnish to BioMed, as soon as
practicable and in any event within 15 days after the end of each calendar quarter, (i) a
capitalization table setting forth all of the capital stock issued and outstanding or issuable by
the Company, including the value of such capital stock, the voting power of such capital stock and
the rights of such capital stock to appoint directors of the Company; provided, however, that so
long as the Company remains subject to the reporting requirements of the Exchange Act, the Company
may satisfy this requirement by timely filing its quarterly reports on Form 10-Q and annual report
on Form 10-K with the Securities and Exchange Commission; and (ii) such other information as is
reasonably requested by BioMed to be necessary or helpful to monitor BioMed’s compliance with the
requirements relating to the status of BioMed or its affiliates as a real estate investment trust
for federal income tax purposes.

2.10 Notification. In the event that the Company becomes aware of any event which has
resulted or which may result in the Shares held by BioMed constituting greater than five percent
(5.0%) of the voting interest and/or greater than five percent (5.0%) of the value of the
outstanding stock of the Company, the Company shall immediately notify BioMed, and in no event
later than five (5) days after the occurrence of such event.

3. Representations and Warranties of BioMed to the Company. BioMed hereby represents
and warrants to the Company as of the Effective Date that:

3.1 Authorization. All corporate action on the part of BioMed, its respective
officers, directors, members and shareholders necessary for the authorization, execution and
delivery of this Agreement, and the performance of all obligations of BioMed hereunder, has been
taken, and such Agreement constitutes a valid and legally binding obligation of BioMed, enforceable
in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of
creditors’ rights generally, and (ii) as limited by laws relating to the availability or specific
performance, injunctive relief, or other equitable remedies.

3.2 No Violation. Neither the execution, delivery and performance of this Agreement
by BioMed nor the acquisition by BioMed of the Shares will violate, conflict with or result in any
breach of any of the terms, conditions or provisions of, constitute a default under, or require any
consent not obtained as of the Effective Date under, (1) the certificate of incorporation or
by-laws of BioMed, (2) any agreement, contract, arrangement or understanding to which BioMed is a
party (including, but not limited to, any shareholders’ or similar agreements), or (3) any statute
or any rule, regulation, order, judgment or decree of any court or other governmental body
applicable to BioMed.

3.3 Investment Experience. BioMed acknowledges that it is an “accredited investor” as
such term is defined in Regulation D promulgated under the Securities Act, that it can bear the
economic risk of its investment, and that it has such knowledge and experience in financial or
business matters that it is capable of evaluating the merits and risks of the investment in the
Shares. BioMed also represents it has not been organized solely for the purpose of acquiring the
Shares.

3.4 Restricted Securities. BioMed understands that the Shares it is purchasing are
characterized as “restricted securities” under the Securities Act inasmuch as they are
being acquired from the Company in a transaction not involving a public offering and that under
such laws and applicable regulations such securities may be resold without registration under the
Securities Act only in certain limited circumstances.

3.5 Legends. It is understood that the certificate(s) evidencing the Shares shall
bear the following legend:

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). SUCH SHARES MAY NOT
BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION UNLESS SUCH
SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY
REQUIREMENTS OF SAID ACT OR UNLESS SOLD PURSUANT TO RULE 144 OF THE ACT.

4. Piggyback Registration. If (but without any obligation to do so) the Company
proposes to register any additional shares of its Common Stock or other securities under the
Securities Act in connection with the public offering of such securities (other than (a) a
registration statement relating to the sale of securities to employees of the Company pursuant to a
stock option, stock purchase or similar plan, (b) a registration statement on Form S-4, or (c) a
registration statement on a form not available for registering the Shares), the Company shall, at
such time, promptly give BioMed written notice of such registration. Upon the written request of
BioMed given within twenty (20) days after mailing of such notice by the Company, the Company shall
use its best efforts to cause to be registered under the Securities Act all of the Shares that
BioMed has requested to be registered; provided, however, that: (i) the Company shall have the
right to postpone or withdraw any registration statement pursuant to this Section 5 without
obligation to BioMed; (ii) of the Shares specified in the written request delivered to the Company
by BioMed, the Company may cut-back and exclude from such registration such number of Shares as is
specified by the Company’s underwriter or investment bank as reasonably necessary in order not to
harm the market for the Common Stock or the underwriting in question, which cut-back shall be
applied pro-rata to all selling stockholders exercising piggyback registration rights in proportion
to the number of shares of Common Stock each seeks to register thereby; and (iii) notwithstanding
anything herein to the contrary, the Company shall not be required to register any Shares if
counsel for the Company opines that such Shares may be sold publicly without restriction by BioMed
without registration under the Securities Act (including in reliance on Rule 144 under the
Securities Act).

5. Miscellaneous.

5.1 Successors and Assigns. Except as otherwise provided herein, the terms and
conditions of this Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties hereto or their respective successors and assigns
any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as
expressly provided in this Agreement.

5.2 Governing Law. This Agreement shall be governed by and construed under the laws
of the State of Washington as applied to agreements entered into and to be performed entirely
within Washington.

5.3 Counterparts. This Agreement may be executed in counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument.

5.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement.

5.5 Notices. All notices and other communications required or permitted hereunder
shall be in writing, shall be effective when given, and shall in any event be deemed to be given
upon receipt or, if earlier, (a) five (5) days after deposit with the U.S. Postal Service or other
applicable postal service, if delivered by first class mail, postage prepaid, (b) upon delivery, if
delivered by hand, (c) one (1) business day after the business day of deposit with Federal Express
or similar overnight courier, freight prepaid or (d) one (1) business day after the business day of
facsimile transmission (with confirmation), if delivered by facsimile transmission with copy by
first class mail, postage prepaid, and shall be addressed (i) if to BioMed, at 17190 Bernardo
Center Drive, San Diego, CA 92128, Attn: General Counsel/Corporate Legal; and (ii) if to the
Company, at the address or facsimile number of the Company’s principal corporate offices, or at
such other address as a party may designate by ten days’ advance written notice to the other party
pursuant to the provisions above.

5.6 Costs and Expenses. Each party shall pay its respective expenses in connection
with the preparation, execution and delivery of this Agreement and the transactions contemplated
hereby, including the fees and out-of-pocket expenses of legal counsel.

5.7 Amendment and Waivers. Any term of this Agreement may be amended and the
severance of any term of this Agreement may be waived (either generally or in a particular instance
and either retroactively or prospectively) only with the written consent of the parties hereto.

5.8 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, such provision shall be excluded from this Agreement and the
balance of the Agreement shall be interpreted as if such provision were so excluded and shall be
enforceable in accordance with its terms.

5.9 Entire Agreement. This Agreement and the documents referred to herein constitute
the entire agreement among the parties and no party shall be liable or bound to any other party in
any manner by any warranties, representations, or covenants except as specifically set forth herein
or therein.

[Remainder of page intentionally left blank.]

1

The parties have executed this Stock Purchase Agreement as of the date first above written.

MDRNA, INC.

By: /s/ J. Michael French

Name: J. Michael French

Title: President and CEO

BIOMED REALTY, L.P.

By: /s/ Kent Griffin

Name: Kent Griffin

Title: President

2EX-10.1

[DEFERRED SETTLEMENT]

RESTRICTED STOCK UNIT AGREEMENT

UNDER THE

LORAL SPACE & COMMUNICATIONS INC.

2005 STOCK INCENTIVE PLAN

THIS AGREEMENT (the “Agreement”) is made as of the 5th day of March, 2009 (the “Grant Date”),
by and between LORAL SPACE & COMMUNICATIONS INC. (the “Company”) and Michael B. Targoff (the
“Grantee”).

W I T N E S S E T H :

WHEREAS, the Grantee is now employed by the Company in a key capacity, and the Company wishes
to grant the Grantee a notional interest in shares of the Company’s common stock, par value $0.01
per share (the “Stock”), in the form of restricted stock units, subject to certain restrictions and
on the terms and conditions set forth herein; and

WHEREAS, through the grant of these restricted stock units, the Company hopes to incentivise
and retain the services of Grantee and encourage stock ownership by Grantee in order to give
Grantee a proprietary interest in the Company’s success and align Grantee’s interest with those of
the stockholders of the Company;

NOW, THEREFORE, in consideration of the covenants and agreements herein contained, the parties
hereto hereby agree as follows:

1. Agreement to Grant Restricted Stock Units. Subject to the restrictions, terms and
conditions set forth herein and in the Company’s 2005 Stock Incentive Plan, as amended from time to
time (the “Plan”), the Company hereby agrees to grant to the Grantee pursuant to the Plan the
restricted stock units set forth below (the restricted stock units granted hereunder are hereafter
referred to as the “Restricted Stock Units”). Each Restricted Stock Unit shall represent the right
to receive upon settlement (i) one share of Stock or (ii) cash equal to the fair market value of
one share of Stock on the settlement date, subject to the terms and conditions set forth herein.
Capitalized terms not defined herein shall have the meaning ascribed to them in the Plan.

(a) Initial Grant. 85,000 of the Restricted Stock Units shall be granted to the
Grantee immediately herewith on the Grant Date (the “Initial Grant”).

(b) Subsequent Grants. Subject to the Grantee’s continued employment with the Company
through the respective grant dates, or as otherwise provided below, 50,000 Restricted Stock Units
shall be granted to the Grantee on the first anniversary of the Grant Date and an additional 40,000
Restricted Stock Units shall be granted to the Grantee on the second anniversary of the Grant Date
(the “Subsequent Grants”) (each separate Subsequent Grant of Restricted Stock Units shall be
hereinafter referred to as a “Tranche”). The period between the Grant Date and the first
anniversary of the Grant Date and the period between the first anniversary of the Grant Date and
the second anniversary of the Grant Date shall each be hereinafter referred to as a “Grant Period.”

2. Satisfaction of Vesting Conditions.

(a) General. Except as provided in this Agreement, the Restricted Stock Units are
subject to a substantial risk of forfeiture until vested as set forth in this Section 2 and are not
transferable, other than by will or the laws of descent and distribution. Vesting of the Initial
Grant of Restricted Stock Units requires the satisfaction of two vesting conditions: a time-based
vesting condition and a stock-price vesting condition. No vesting of the Initial Grant of
Restricted Stock Units will occur unless both vesting conditions are satisfied. Because both the
time-based vesting condition and the stock-price vesting condition must be satisfied for the
Initial Grant of Restricted Stock Units to vest, to the extent that one vesting condition is
satisfied prior to the satisfaction of the other vesting condition, vesting will be delayed until
the date that both vesting conditions are satisfied. Vesting of the Subsequent Grants of
Restricted Stock Units shall be subject only to the stock-price vesting condition.

(i) Time-Based Vesting Condition. Except as specifically set forth below in Sections
2(b) and 2(c), in the event of the Grantee’s death, Disability, or termination without Cause (as
defined below) or for Good Reason (as defined below), as applicable, the time-based vesting
condition of the Initial Grant of Restricted Stock Units will be satisfied upon the Grantee’s
continued employment with the Company or a subsidiary of the Company (a “Subsidiary”) from the
Grant Date through the first anniversary of the Grant Date (the period during which employment is
required to be continued is hereafter referred to as the “Time-Based Vesting Period,” and the date
through which employment is required to continue is hereafter referred to as the “Time-Based
Vesting Date”).

(ii) Stock-Price Vesting Condition. Except as specifically set forth below in
Sections 2(b) and 2(c), in the event of the Grantee’s death, Disability, or termination without
Cause (as defined below) or for Good Reason (as defined below), as applicable, the stock price
vesting condition for all Restricted Stock Units will be satisfied on the last day of the first
20-consecutive-trading-day-period after the Grant Date during which the average closing price of
the Stock over such period is equal to or greater than $25, which occurs (1) while the Grantee
remains employed with the Company or a Subsidiary (the “Stock-Price Employment Condition”) and (2)
on or prior to March 31, 2013 (the “Stock-Price Vesting Condition”).

(b) Death or Disability.

(i) Subsequent Grants. Notwithstanding the continued employment requirement set forth
in Section 1 above, upon the Grantee’s death or Disability (as defined below) while employed with
the Company or a Subsidiary, a portion of the then ungranted Subsequent Grant Tranche of Restricted
Stock Units next scheduled to be granted to the Grantee shall be immediately granted to the Grantee
equal to the number of Restricted Stock Units subject to such next Tranche multiplied by a
fraction, the denominator of which is the total number of days in the Grant Period during which
such death or Disability occurs, and the numerator of which is the number of days during such Grant
Period that the Grantee is employed with the Company or a Subsidiary prior to such death or
Disability. For purposes of this Agreement, the term “Disability” shall have the meaning ascribed
thereto in the Employment Agreement, dated as of March 26, 2006 and amended and restated as of
December, 17, 2008 between the Grantee and the Company (the “Employment Agreement”), provided such
Disability also constitutes a “disability” within the meaning of Treasury Regulation Section
1.409A-3(i)(4). Except as provided in this Section 2(b)(i), upon the Grantee’s death or
Disability, the ungranted portion of the Subsequent Grants shall expire and be forfeited and the
Company shall be relieved of its obligation to grant any further of the Subsequent Grants.

(ii) Time-Based Vesting Condition. Notwithstanding the general vesting provisions
contained in Section 2(a)(i) above, upon the Grantee’s death or Disability prior to the Time-Based
Vesting Date, the time-based vesting condition will be satisfied with respect to a portion of the
Initial Grant of Restricted Stock Units equal to the number of Restricted Stock Units subject to
such Initial Grant of Restricted Stock Units multiplied by a fraction, the denominator of which is
three hundred and sixty-five (365) and the numerator of which is the number of days during the
Time-Based Vesting Period that the Grantee is employed with the Company or a Subsidiary prior to
such event.

(iii) Stock-Price Vesting Condition. Notwithstanding the general vesting provisions
contained in Section 2(a)(ii) above, upon the Grantee’s death or Disability, the Stock-Price
Employment Condition will be waived for the one-year period immediately following such event (or
until March 31, 2013, if earlier) and if following such death or Disability but prior to the
earlier of (1) the end of such one-year period or (2) March 31, 2013, the average closing price of
the Stock during any 20-consecutive-trading-day-period is equal to or greater than $25, the
Stock-Price Vesting Condition shall be satisfied.

(c) Termination Without Cause.

(i) Subsequent Grants. Notwithstanding the continued employment requirement set forth
in Section 1 above, upon the termination of the Grantee’s employment with the Company and all
Subsidiaries by the Company or a Subsidiary without Cause (as that term is defined in the
Employment Agreement) or by the Grantee for Good Reason (as that term is defined in the Employment
Agreement), in each case, following the first anniversary of the Grant Date, all of the then
ungranted Subsequent Grants shall be immediately granted to the Grantee. Except as provided in
this Section 2(c)(i), upon the termination of the Grantee’s employment with the Company and all
Subsidiaries by the Company or a Subsidiary without Cause, the ungranted portion of the Subsequent
Grants shall expire and be forfeited and the Company shall be relieved of its obligation to grant
any further of the Subsequent Grants.

(ii) Stock-Price Vesting Condition. Notwithstanding the general vesting provisions
contained in Section 2(a)(ii) above, upon the termination of the Grantee’s employment with the
Company and all Subsidiaries of the Company by the Company or a Subsidiary without Cause or by the
Grantee for Good Reason, in each case, following the first anniversary of the Grant Date, the
Stock-Price Employment Condition will be waived for the one-year period immediately following such
termination (or until March 31, 2013, if earlier) and if, following such termination date but prior
to the earlier of (1) the end of such one-year post-termination period or (2) March 13, 2013, the
average closing price of the Stock during any 20-consecutive-trading-day-period is equal to or
greater than $25, the Stock-Price Vesting Condition shall be satisfied.

(d) Other Terminations. Upon the Grantee’s termination of employment with the Company
and all Subsidiaries of the Company for any reason other than by the Company or a Subsidiary
without Cause or by the Grantee for Good Reason, (i) all outstanding unvested Restricted Stock
Units shall immediately expire and be forfeited and (ii) the ungranted portion of the Subsequent
Grants shall expire and be forfeited and the Company shall be relieved of its obligation to grant
any further of the Subsequent Grants.

(e) Change in Control.

(i) Subsequent Grants. In the event of a Change in Control that also constitutes a
“change in control event” within the meaning of Treasury Regulation Section 1.409A-3(i)(5) (a “409A
Change in Control”), all of the then ungranted Subsequent Grants shall be immediately granted to
the Grantee.

(ii) Time-Based Vesting Condition. In the event of a 409A Change in Control prior to
the date the time-based vesting condition with respect to the Initial Grant of Restricted Stock
Units is satisfied, such time-based vesting condition will be immediately satisfied with respect to
all of the Restricted Stock Units granted as part of the Initial Grant.

(iii) Stock-Price Vesting Condition. In the event of a Change in Control, (1) if the
Company’s stockholders receive a per-share value for their shares of Stock in the Change-in-Control
transaction equal to or greater than $25, the Stock-Price Vesting Condition shall be fully
satisfied, as of the date of the consummation of such Change in Control transaction or (2) if the
Company’s stockholders receive a per-share value for their shares of Stock in the Change-in-Control
transaction equal to or greater than the closing price of the Stock on the Grant Date but less than
$25, the Stock-Price Vesting Condition shall be satisfied, as of the date of the consummation of
such Change in Control transaction, with respect to a portion of the Restricted Stock Units equal
to the total number of Restricted Stock Units multiplied by a fraction, the numerator of which
shall be the per-share value received by the Company’s stockholders for their shares of Stock in
the Change-in-Control transaction and the denominator of which shall be $25, or (3) if the
Company’s stockholders receive a per-share value for their shares of Stock in the Change-in-Control
transaction equal to less than the closing price of the Stock on the Grant Date, the Stock-Price
Vesting Condition shall not be satisfied and to the extent that the Stock-Price Vesting Condition
has not previously been satisfied as of the date of the consummation of such Change in Control
transaction, all unvested Restricted Stock Units shall be forfeited.

3. Settlement of Restricted Stock Units.

(a) All outstanding vested Restricted Stock Units shall be settled on the earlier of (a) March
31, 2013, (b) the date of the Grantee’s death or Disability, (c) the date the Grantee undergoes a
Separation from Service (as defined below), and (d) the date of consummation of a 409A Change in
Control, (the first of (a), (b), (c) and (d) to occur shall be the “Settlement Date”);
provided, however, that in the event of Grantee’s death or Disability, or if the
Company or a Subsidiary terminates the Grantee’s employment without Cause, or upon the Grantee’s
termination of employment for Good Reason, in each event, following the first anniversary of the
Grant Date but prior to the date that the Stock-Price Vesting Condition has been satisfied,
settlement shall be delayed and all Restricted Stock Units with respect to which the time-based
vesting condition has been satisfied as of the date of such death, Disability or termination, shall
become vested and settled on the date the Stock-Price Vesting Condition becomes satisfied during
the period ending on the earlier to occur of (x) the first anniversary of such death, Disability or
termination and (y) March 31, 2013 (such settlement date, also a “Settlement Date”); and
provided further, however, that to the extent that the Grantee is a
“specified employee” within the meaning of Treasury Regulation 1.409A-1(i) any settlement of the
Restricted Stock Units on account of the Grantee’s Separation from Service from the Company shall
be delayed for such period of time as may be necessary to meet the requirements of Treasury
Regulation Section 1.409A-3(i)(2) (the “Delay Period”) and on the first business day
following the expiration of the Delay Period, all vested Restricted Stock Units shall be settled.
On the Settlement Date, the Company shall deliver to the Grantee (or the Grantee’s estate in the
event of Grantee’s death) (x) a certificate or certificates representing the number of shares of
Stock equal to the number of vested Restricted Stock Units or (y) a lump sum payment of cash having
a value equal to the fair market value of one share of Stock as of the Settlement Date multiplied
by the number of vested Restricted Stock Units. The determination as to whether the Restricted
Stock Units will be settled in Stock or cash shall be within the sole discretion of the Company.

(b) For purposes of this Agreement, a “Separation from Service” will be deemed to occur on the
date as of which the Grantee has undergone a “termination of employment” (as that term is
specifically defined in Treas. Reg. §1.409A-1(h)(ii) applying the rules set forth therein) with the
Loral Controlled Group (as defined below); provided, however, that the Grantee will
be deemed to undergo a termination of employment (and thus a Separation from Service) on the date
that such Grantee’s level of bona fide services performed decreases to a level less than 50 percent
of the average level of services performed by the Grantee during the immediately preceding 36-month
period. For purposes of this Agreement the Loral Controlled Group means Loral and all persons and
entities with respect to which Loral would be considered a single employer under Code §414(b) and
(c), provided, however, that in applying Code §1563(a)(1), (2) and (3) for purposes
of determining a controlled group of corporations and in applying Treas. Reg. §1.414(c)-2 for
purposes of determining trades or businesses that are under common control, as provided in Treas.
Reg. §1.409A-1(h)(3), the language “at least 80 percent” is used, instead of the default language
“at least 50 percent” as set forth in Treas. Reg. §1.409A-1(h)(3), each place it appears.

4. Dividends and Dividend Equivalents. No dividends or dividend equivalents shall accrue or
be paid with respect to any outstanding Restricted Stock Units.

5. Rights of Stockholder. The Grantee will not have any rights as a Stockholder with respect
to any Restricted Stock Units until the Grantee becomes the holder of record of such shares.

6. No Right to Continued Employment. This Agreement does not confer upon the Grantee any
right to continuance of employment with the Company, nor shall it interfere in any way with the
right of the Company to terminate his or her employment at any time.

7. Transferability. The Restricted Stock Units may not, at any time prior to settlement, be
assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Grantee
other than by will or the laws of descent and distribution and any such purported assignment,
alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable.

8. Tax Withholding. The Grantee agrees as a condition of this Agreement, to pay to the
Company, or make arrangements satisfactory to the Company regarding payment to the Company of, the
aggregate amount of federal, state and local income and payroll taxes that the Company is required
to withhold in connection with the vesting and settlement of the Restricted Stock Units.
Alternatively, the Company may, in its sole discretion, withhold cash and/or shares of Stock having
a value equal to all or a portion of the aggregate minimum amount of federal, state and local
income and payroll taxes that the Company is required to withhold, and, if only a portion of the
required amount is withheld, the Grantee agrees to pay to the Company, or make arrangements
satisfactory to the Company regarding payment to the Company of, the amount of tax withholding not
covered by the withholding of cash and/or shares of Stock.

9. Notice. Every notice or other communication relating to this Agreement shall be in
writing, and shall be mailed to or delivered to the party for whom it is intended at such address
as may from time to time be designated by it in a notice mailed or delivered to the other party as
herein provided; provided that, unless and until some other address be so designated, all notices
or communications by the Grantee to the Company shall be mailed or delivered to the Company at its
New York office and all notices or communications by the Company to the Grantee may be given to the
Grantee personally or may be mailed to the Grantee’s home address as reflected on the books of the
Company.

10. Arbitration. All disputes between the parties arising out of, or in connection with the
validity, interpretation, construction, meaning or execution of the Plan or of this Agreement or
any settlement thereof, shall be finally settled by arbitration to be held in New York City and
conducted in accordance with the Rules of the American Arbitration Association. Judgment upon the
award rendered may be entered in any court having jurisdiction or application may be made to such
court for judicial acceptance of the award and an order of enforcement, as the case may be.

11. Governing Law. The validity, interpretation and performance of this Agreement shall be
controlled by and construed under the laws of Delaware, without giving effect to the principles of
conflicts of law.

12. Employment Agreement Superseded. This Agreement governs the terms and conditions of the
Restricted Stock Units and supersedes the Employment Agreement and all other agreements and
arrangements as they may relate to the Restricted Stock Units.

13. Signature in Counterparts. This Agreement may be signed in counterparts, each of which
shall be an original, with the same effect as if the signatures thereto and hereto were upon the
same instrument.

* * *

1

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first
above written.

LORAL SPACE & COMMUNICATIONS INC.

By: /s/ Avi Katz

Name: Avi Katz

Title: Senior Vice President, General Counsel and

Secretary

/s/ Michael B. Targoff

	 	 	Grantee: Michael B. Targoff

Mailing Address of Grantee for Delivery of Stock Certificates:

      

      

Phone Number of Grantee:      

Email Address of Grantee:      

Social Security No.:      —      —      

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]